West Nile Virus Infections - Pipeline Review, H2 2016

Date: September 21, 2016
Pages: 71
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: W7AE4BADEA8EN
Leaflet:

Download PDF Leaflet

West Nile Virus Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘West Nile Virus Infections - Pipeline Review, H2 2016’, provides an overview of the West Nile Virus Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for West Nile Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for West Nile Virus Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape of West Nile Virus Infections
  • The report reviews pipeline therapeutics for West Nile Virus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved West Nile Virus Infections therapeutics and enlists all their major and minor projects
  • The report assesses West Nile Virus Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for West Nile Virus Infections
Reasons to buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for West Nile Virus Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding West Nile Virus Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope:
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
West Nile Virus Infections Overview
Therapeutics Development
Pipeline Products for West Nile Virus Infections - Overview
Pipeline Products for West Nile Virus Infections - Comparative Analysis
West Nile Virus Infections - Therapeutics under Development by Companies
West Nile Virus Infections - Therapeutics under Investigation by Universities/Institutes
West Nile Virus Infections - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
West Nile Virus Infections - Products under Development by Companies
West Nile Virus Infections - Products under Investigation by Universities/Institutes
West Nile Virus Infections - Companies Involved in Therapeutics Development
CEL-SCI Corporation
Hemispherx Biopharma, Inc.
Kineta, Inc.
Nanotherapeutics, Inc.
Plex Pharmaceuticals, Inc.
West Nile Virus Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Alferon LDO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BG-323 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FDX-000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HydroVax-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon alfa-n3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIN-1148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIN-1400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for West Nile Virus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rintatolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RL-15A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit NS2B-NS3 Protease for Dengue, Zika and West Nile Virus Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Dengue Virus and West Nile Virus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tatbeclin-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
West Nile virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
West Nile virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
West Nile Virus Infections - Dormant Projects
West Nile Virus Infections - Product Development Milestones
Featured News & Press Releases
Jul 06, 2015: NIH-funded vaccine for West Nile Virus enters human clinical trials
May 05, 2014: Alferon N Effective Against MERS Virus In-Vitro
Sep 12, 2013: Hemispherx Announces Initial Test Results in Biosecurity/Biodefense Arena
Sep 06, 2011: Hemispherx Enters Into Strategic Alliance With Armada Health Care For Alferon N Injection
Apr 20, 2010: Kineta Scientist to Present Novel Antiviral Research Findings at International Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 71

LIST OF TABLES

Number of Products under Development for West Nile Virus Infections, H2 2016
Number of Products under Development for West Nile Virus Infections - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
West Nile Virus Infections - Pipeline by CEL-SCI Corporation, H2 2016
West Nile Virus Infections - Pipeline by Hemispherx Biopharma, Inc., H2 2016
West Nile Virus Infections - Pipeline by Kineta, Inc., H2 2016
West Nile Virus Infections - Pipeline by Nanotherapeutics, Inc., H2 2016
West Nile Virus Infections - Pipeline by Plex Pharmaceuticals, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
West Nile Virus Infections - Dormant Projects, H2 2016
West Nile Virus Infections - Dormant Projects (Contd..1), H2 2016
West Nile Virus Infections - Dormant Projects (Contd..2), H2 2016 65

LIST OF FIGURES

Number of Products under Development for West Nile Virus Infections, H2 2016
Number of Products under Development for West Nile Virus Infections - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

West Nile Virus Infections - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: